Member Profile

PharmaEssentia Corporation aims to deliver efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to our stakeholders. At PharmaEssentia, our mission is a never-ceasing commitment to the improvement of health and quality of life. PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading biotechnology and pharmaceutical companies in the US, with a goal to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases.

Our flagship product is a new generation ropeginterferon alfa-2b (P1101), developed using our novel PEGylation technology platform. This has resulted in a much purer pegylated interferon (>90% 1 predominant isomer vs. PegIntron’s 14 isomers and Pegasys’ 8 isomers). The main problem with the current pegylated interferons (PegIntron and Pegasys) are patient tolerability, as these drugs induce severe flu-like symptoms and neuropsychiatric side effects. As a result of our purer profile, we have seen data that indicates improved tolerability, compliance and thus long-term treatment outcomes. We are able to administer our product once every two weeks (vs. every week for other pegylated interferons) for enhanced tolerability. We plan to explore ropeginterferon alfa-2b in a variety of indications, including myeloproliferative neoplasms (MPNs) and hepatitis B and C.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2017 PharmaEssentia approves EMA’s PAI (Pre-Approval Inspection) for PV.
   2018 The data of P1101 (Ropeginterferon alfa-2b) for PV in Phase III shows superiority in Durable Response for HU patients.
   2018 AOP, the partner of PharmaEssentia in EU, has submitted the D120 LoQ to EMA and is expected to obtain the approval at the end of 2018.
   2019 The Marketing Authorization For Ropeginterferon alfa-2b (Besremi) is granted by EMA.